MAP Peptide Anti-Inflammatory Use for Wound Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammation and inflammatory disorders often have limitations, such as causing harm to wound healing processes when applied to open wounds and lacking effective management of inflammatory symptoms like pain and itching.
Innovation Solution
The use of the MAP Peptide, specifically the Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys peptide or its salts, which are administered topically or systemically to treat inflammation, pain, and prevent fluid exudation, infection, and scarring, while promoting wound healing and reducing melanin pigmentation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If traditional anti-inflammatory drugs are applied to open wounds, then inflammation is suppressed, but wound healing is harmed
Solution Approach 1:
The patent segments the anti-inflammatory activity from the wound healing process by using a peptide that specifically targets inflammatory mediators without interfering with wound healing pathways. The peptide acts selectively on inflammatory cells and molecules, allowing inflammation suppression while preserving wound healing capabilities.
Solution Approach 2:
The peptide acts as an intermediary substance that mediates between the harmful inflammatory response and the beneficial wound healing process. It binds to and neutralizes inflammatory mediators (such as cytokines and chemokines) without blocking wound healing signals, thus resolving the contradiction between suppressing inflammation and maintaining healing.
2Object-affected harmful factors
If conventional anti-inflammatory treatments are used, then inflammation is reduced, but pain and itching symptoms are not effectively managed
Solution Approach 1:
The peptide exhibits multi-functionality by simultaneously addressing multiple inflammatory-related symptoms. It suppresses inflammation through binding to inflammatory mediators, while also providing analgesic (pain relief) and antipruritic (itch relief) effects, thereby managing multiple symptoms through a single agent.
Solution Approach 2:
The patent utilizes the specific molecular structure and charge properties of the peptide (positive charge at physiological pH) to change the interaction parameters with inflammatory cells and tissue components. This enables the peptide to penetrate inflammatory sites and bind to negatively charged inflammatory mediators, effectively managing symptoms through modified biochemical parameters.
3Object-affected harmful factors
If existing anti-inflammatory drugs are administered, then inflammation is treated, but side effects increase
Solution Approach 1:
The peptide is a small, simple molecular structure compared to conventional anti-inflammatory drugs. Its small size and simple chemistry reduce the complexity of its molecular interactions, minimizing off-target effects and side reactions while maintaining effective anti-inflammatory activity.
Solution Approach 2:
The patent extracts and isolates the specific anti-inflammatory active components from complex drug molecules. By using a purified peptide with defined amino acid sequence and structure, the invention removes unnecessary chemical complexity that would generate side effects, retaining only the essential anti-inflammatory function.
Data Source
AI summary
Provided a peptide of the sequence Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys or a salt thereof for use in the treatment of inflammation, of an inflammatory disorder and/or of ion thea condition characterized by inflammation, including wounds, burns, psoriasis, acne and atopic dermatitis.